INmune Bio, Inc. (INMB)

Over the past 12 months, INmune Bio's stock has experienced a significant decline, losing 82.5% of its value. Institutional ownership saw a minor decrease of approximately -0.19% in the most recent reported period. In November 2025, institutional ownership climbed to roughly 21.21%. On February 12, 2026, the company announced FDA alignment on an integrated Phase 2b/3 registration pathway for XPro1595 in early Alzheimer's Disease, which was followed by a -6.37% change in stock price. On February 19, 2026, INmune Bio announced an upcoming webinar to present new clinical data on CORDStrom™ for RDEB, resulting in a -2.22% stock price change. On February 23, 2026, the company detailed its XPro1595 Registrational Strategy in an Alzheimer's webinar, with the stock seeing a -3.82% change. In March 2026, INmune Bio's MINDFuL Trial was featured at the AD/PD 2026 Plenary, leading to a -1.61% change. On March 30, 2026, INmune Bio Inc. announced its 2025 results and provided a business update, with the stock declining -0.9% the day following this earnings announcement. The company reported a net loss of $45.9 million for 2025. The stock experienced further daily fluctuations in late March/early April 2026.

As a clinical-stage biotechnology company, INmune Bio, Inc. currently has minimal revenue and is focused on research, development, and regulatory approvals rather than commercial product sales. Therefore, traditional demand seasonality is not applicable to INmune Bio's current business model. Its financial performance and stock valuation are primarily driven by clinical trial milestones, regulatory progress, and funding rounds.

INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments targeting the innate immune system to combat diseases. The company operates in the Healthcare sector, specifically within the Biotechnology and Drug Discovery industry. INmune Bio focuses on inflammation and immunology, with product platforms designed to address diseases driven by chronic inflammation and cancer by modulating innate immune dysfunction. The company's pipeline includes the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform (XPro™), the CORDStrom™ platform, and the INKmune® platform. As a clinical-stage company, INmune Bio's product candidates have not yet received FDA approval. The company reported $50K in revenue over the trailing twelve months as of December 31, 2025.

INmune Bio, Inc. is incorporated in Nevada, USA, with principal executive offices in Boca Raton, Florida. The company's common stock trades on The Nasdaq Stock Market LLC under the symbol INMB. Regulatory filings and clinical trial activities are underway for potential approvals in the United States, the United Kingdom, and the European Union. In January 2026, the company received an Australian R&D rebate of $3.6 million USD.

INmune Bio's brand reputation in the past year appears to be mixed, influenced by its clinical-stage nature and stock performance. The company has received a consensus rating of "Hold" from analysts, with an average rating score of 2.17. Positive events contributing to its reputation include the MINDFuL trial for Alzheimer's disease being featured at the AD/PD 2026 Plenary and FDA alignment on an integrated Phase 2b/3 registration pathway for XPro1595 in early Alzheimer's Disease. The company's reputation has likely been impacted by a significant stock price decline, a "pipeline reset", and the company being pre-revenue and operating at a net loss.

The ownership structure of INmune Bio (INMB) stock is a mix of institutional, insider, and retail/public investors. As of late 2025, institutional investors held around 21.21% of the shares, insiders held approximately 17.48%, and retail/public ownership accounted for roughly 71.34%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., Geode Capital Management, Llc, and State Street Corp. Among individual owners, Mark William Lowdell is reported to own the most shares of INmune Bio (INMB).